Blueprint Medicines to Present Updated Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma at ESMO 2017 Congress and 11th ILCA Annual Conference
At ESMO and ILCA,
"The preliminary BLU-554 data announced today continue to provide support for selective FGFR4 inhibition as a novel targeted treatment approach in biomarker-selected patients with hepatocellular carcinoma," said
Details of the presentations are as follows:
2017
Presentation Title: Phase 1 Safety and Clinical Activity of BLU-554 in Advanced Hepatocellular Carcinoma (HCC)
Session Title: Developmental Therapeutics
Date & Time:
Abstract ID: 365O
Location:
11th ILCA Annual Conference
Presentation Title: Clinical Activity Of BLU-554, A Potent, Highly-Selective FGFR4 Inhibitor In Advanced Hepatocellular Carcinoma (HCC) With FGFR4 Pathway Activation
Session Title: General Session 5
Date & Time:
Abstract No: O-032
Location: Grand Hyatt Seoul
Conference Call and Webcast Information
About
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans and timelines for
View original content with multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-updated-data-from-ongoing-phase-1-clinical-trial-of-blu-554-in-patients-with-advanced-hepatocellular-carcinoma-at-esmo-2017-congress-and-11th-ilca-annual-conference-300507005.html
SOURCE
Kristin Hodous, 617-714-6674, khodous@blueprintmedicines.com; or Jim Baker, 617-844-8236, jbaker@blueprintmedicines.com